HealthDay News – mRNA-COVID-19 vaccines offer protection against infection in nursing home residents, but the vaccine’s effectiveness was lower after the Delta variant became the predominant strain, according to a study published in the US Centers edition for. published Aug. 18 Weekly Report on Morbidity and Mortality for Disease Control and Prevention.
Srinivas Nanduri, MD, of the CDC COVID-19 Response Team, and colleagues analyzed weekly data reported by Centers for Medicare & Medicaid-certified qualified nursing homes or nursing homes to determine the effectiveness of full vaccination with the two currently approved mRNA COVID- 19 vaccines to be evaluated shortly after the vaccine was launched (March 1 to May 9, 2021; pre-delta period) and when the delta variant prevailed (June 21 to August 1, 2021).
The researchers found that the adjusted anti-infection efficacy for each mRNA vaccine in the pre-delta period was 74.7%, using 17,407 weekly reports from 3,862 facilities. During an interim period (May 10 to June 20), the adjusted effectiveness was 67.5% using 33,160 weekly reports from 11,581 facilities. During the delta period, adjusted effectiveness was 53.1% using 85,593 weekly reports from 14,917 facilities. Similar efficacy estimates have been reported for the Pfizer-BioNTech and Moderna vaccines.
Continue reading
“In order to prevent the transmission of SARS-CoV-2 in nursing homes, these results underscore the crucial importance of COVID-19 vaccination for employees, residents and visitors and compliance with strict COVID-19 prevention strategies,” the authors write. “An additional dose of the COVID-19 vaccine could be considered for residents of nursing homes and long-term care facilities to optimize a protective immune response.”
Summary / full text
Subjects:
COVID19 COVID19 Vaccines Preventive Medicine
